Consequences of splice variation on Secretin family G protein‐coupled receptor function

The Secretin family of GPCRs are endocrine peptide hormone receptors that share a common genomic organization and are the subject of a wide variety of alternative splicing. All GPCRs contain a central seven transmembrane domain responsible for transducing signals from the outside of the cell as well as extracellular amino and intracellular carboxyl termini. Members of the Secretin receptor family have a relatively large N‐terminus and a variety of lines of evidence support a common mode of ligand binding and a common ligand binding fold. These receptors are best characterized as coupling to intracellular signalling pathways via Gαs and Gαq but are also reported to couple to a multitude of other signalling pathways. The intracellular loops are implicated in regulating the interaction between the receptor and heterotrimeric G protein complexes. Alternative splicing of exons encoding both the extracellular N‐terminal domain as well as the extracellular loops of some family members has been reported and as expected these splice variants display altered ligand affinity as well as differential activation by endogenous ligands. Various forms of alternative splicing have also been reported to alter intracellular loops 1 and 3 as well as the C‐terminus and as one might expect these display differences in signalling bias towards downstream effectors. These diverse pharmacologies require that the physiological role of these splice variants be addressed but should provide unique opportunities for drug design and development.

[1]  J. Tesmer,et al.  Recognition in the Face of Diversity: Interactions of Heterotrimeric G proteins and G Protein-coupled Receptor (GPCR) Kinases with Activated GPCRs* , 2011, The Journal of Biological Chemistry.

[2]  P. A. Friedman,et al.  A Naturally Occurring Isoform Inhibits Parathyroid Hormone Receptor Trafficking and Signaling , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  H. Xu,et al.  Structural Basis for Hormone Recognition by the Human CRFR2α G Protein-coupled Receptor* , 2010, The Journal of Biological Chemistry.

[4]  L. Eiden,et al.  PAC1hop receptor activation facilitates catecholamine secretion selectively through 2-APB-sensitive Ca(2+) channels in PC12 cells. , 2010, Cellular signalling.

[5]  P. Sexton,et al.  Importance of lipid-exposed residues in transmembrane segment four for family B calcitonin receptor homo-dimerization , 2010, Regulatory Peptides.

[6]  C. Koth,et al.  Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. , 2010, Structure.

[7]  P. Sexton,et al.  Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening , 2010, Molecular Pharmacology.

[8]  A. Slominski,et al.  Emerging role of alternative splicing of CRF1 receptor in CRF signaling. , 2010, Acta biochimica Polonica.

[9]  A. Slominski,et al.  Modulation of corticotropin releasing factor (CRF) signaling through receptor splicing in mouse pituitary cell line AtT-20--emerging role of soluble isoforms. , 2009, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[10]  A. Seasholtz,et al.  Soluble corticotropin-releasing hormone receptor 2alpha splice variant is efficiently translated but not trafficked for secretion. , 2009, Endocrinology.

[11]  Ruben Abagyan,et al.  Functional Importance of a Structurally Distinct Homodimeric Complex of the Family B G Protein-Coupled Secretin Receptor , 2009, Molecular Pharmacology.

[12]  A. Slominski,et al.  CRF1 receptor splicing in epidermal keratinocytes: Potential biological role and environmental regulations , 2009, Journal of cellular physiology.

[13]  H. Xu,et al.  Molecular Recognition of Corticotropin-releasing Factor by Its G-protein-coupled Receptor CRFR1* , 2008, Journal of Biological Chemistry.

[14]  H. Lehnert,et al.  Structural determinants critical for localization and signaling within the seventh transmembrane domain of the type 1 corticotropin releasing hormone receptor: lessons from the receptor variant R1d. , 2008, Molecular endocrinology.

[15]  L. Miller,et al.  Dimerization in the absence of higher-order oligomerization of the G protein-coupled secretin receptor. , 2008, Biochimica et biophysica acta.

[16]  Sylvain Foissac,et al.  A General Definition and Nomenclature for Alternative Splicing Events , 2008, PLoS Comput. Biol..

[17]  Kjeld Madsen,et al.  Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain* , 2008, Journal of Biological Chemistry.

[18]  H. Xu,et al.  Molecular recognition of parathyroid hormone by its G protein-coupled receptor , 2008, Proceedings of the National Academy of Sciences.

[19]  M. Levine,et al.  Structural domains determining signalling characteristics of the CRH-receptor type 1 variant R1beta and response to PKC phosphorylation. , 2008, Cellular signalling.

[20]  N. Sultana,et al.  Headless splice variant acting as dominant negative calcitonin receptor. , 2007, Biochemical and biophysical research communications.

[21]  L. Miller,et al.  Transmembrane Segment IV Contributes a Functionally Important Interface for Oligomerization of the Class II G Protein-coupled Secretin Receptor* , 2007, Journal of Biological Chemistry.

[22]  Y. Takei,et al.  Fish calcitonin receptor has novel features. , 2007, General and comparative endocrinology.

[23]  R. Rudolph,et al.  Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor , 2007, Proceedings of the National Academy of Sciences.

[24]  K. Mori,et al.  Differential Intracellular Signaling through PAC1 Isoforms as a Result of Alternative Splicing in the First Extracellular Domain and the Third Intracellular Loop , 2007, Molecular Pharmacology.

[25]  P. Hajduk,et al.  Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS , 2007, Proceedings of the National Academy of Sciences.

[26]  R. Riek,et al.  Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand , 2007, Proceedings of the National Academy of Sciences.

[27]  L. Eiden,et al.  The Hop Cassette of the PAC1 Receptor Confers Coupling to Ca2+ Elevation Required for Pituitary Adenylate Cyclase-activating Polypeptide-evoked Neurosecretion* , 2007, Journal of Biological Chemistry.

[28]  H. Randeva,et al.  Differential Responses of Corticotropin-Releasing Hormone Receptor Type 1 Variants to Protein Kinase C Phosphorylation , 2006, Journal of Pharmacology and Experimental Therapeutics.

[29]  M. Johnson,et al.  Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: Consequences for signaling by VIP and PACAP , 2006, Molecular and Cellular Neuroscience.

[30]  L. Miller,et al.  Paired Cysteine Mutagenesis to Establish the Pattern of Disulfide Bonds in the Functional Intact Secretin Receptor* , 2005, Journal of Biological Chemistry.

[31]  J. Vaughan,et al.  A soluble mouse brain splice variant of type 2alpha corticotropin-releasing factor (CRF) receptor binds ligands and modulates their activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  B. Wiesner,et al.  Dimerization of Corticotropin-Releasing Factor Receptor Type 1 Is Not Coupled to Ligand Binding , 2005, Journal of receptor and signal transduction research.

[33]  Charles E. Chapple,et al.  Genome duplication in the teleost fish Tetraodon nigroviridis reveals the early vertebrate proto-karyotype , 2004, Nature.

[34]  J. Furkert,et al.  Regulation of the Coupling to Different G Proteins of Rat Corticotropin-releasing Factor Receptor Type 1 in Human Embryonic Kidney 293 Cells* , 2004, Journal of Biological Chemistry.

[35]  R. Riek,et al.  NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  H. Schiöth,et al.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.

[37]  W. Fischer,et al.  A Soluble Form of the First Extracellular Domain of Mouse Type 2β Corticotropin-releasing Factor Receptor Reveals Differential Ligand Specificity* , 2003, The Journal of Biological Chemistry.

[38]  B. Wulff,et al.  Different domains of the glucagon and glucagon‐like peptide‐1 receptors provide the critical determinants of ligand selectivity , 2003, British journal of pharmacology.

[39]  P. Sexton,et al.  Novel Receptor Partners and Function of Receptor Activity-modifying Proteins* , 2003, The Journal of Biological Chemistry.

[40]  L. Miller,et al.  Silencing of secretin receptor function by dimerization with a misspliced variant secretin receptor in ductal pancreatic adenocarcinoma. , 2002, Cancer research.

[41]  R. Rudolph,et al.  In vitro folding, functional characterization, and disulfide pattern of the extracellular domain of human GLP-1 receptor. , 2002, Biophysical chemistry.

[42]  L. Miller,et al.  Dominant negative action of an abnormal secretin receptor arising from mRNA missplicing in a gastrinoma. , 2002, Gastroenterology.

[43]  A. Slominski,et al.  Alternative splicing of CRH‐R1 receptors in human and mouse skin: identification of new variants and their differential expression , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  W. Fischer,et al.  Expression, Purification, and Characterization of a Soluble Form of the First Extracellular Domain of the Human Type 1 Corticotropin Releasing Factor Receptor* , 2001, The Journal of Biological Chemistry.

[45]  J. Habener,et al.  Novel Alternatively Spliced Exon in the Extracellular Ligand-binding Domain of the Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) Type 1 Receptor (PAC1R) Selectively Increases Ligand Affinity and Alters Signal Transduction Coupling during Spermatogenesis* , 2001, The Journal of Biological Chemistry.

[46]  A. Evdokiou,et al.  Sustained activation of Erk1/2 MAPK and cell growth suppression by the insert-negative, but not the insert-positive isoform of the human calcitonin receptor. , 2000, The Journal of endocrinology.

[47]  R. Rudolph,et al.  The N-terminal fragment of human parathyroid hormone receptor 1 constitutes a hormone binding domain and reveals a distinct disulfide pattern. , 2000, Biochemistry.

[48]  R. Hauger,et al.  N‐Terminal Splice Variants of the Type I PACAP Receptor: Isolation, Characterization and Ligand Binding/Selectivity Determinants , 1999, Journal of neuroendocrinology.

[49]  Gavin Kilpatrick,et al.  Human CRF2 α and β splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay , 1999, Neuropharmacology.

[50]  Gavin Kilpatrick,et al.  Human CRF2 alpha and beta splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay. , 1999, Neuropharmacology.

[51]  B. Largent,et al.  Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. , 1998, Molecular endocrinology.

[52]  P. Sexton,et al.  Function of the rat calcitonin receptors, C1a and C1b, expressed in Xenopus oocytes. , 1998, Biochemical and biophysical research communications.

[53]  C. Montrose‐Rafizadeh,et al.  High Potency Antagonists of the Pancreatic Glucagon-like Peptide-1 Receptor* , 1997, The Journal of Biological Chemistry.

[54]  R. Pederson,et al.  Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor. , 1997, Endocrinology.

[55]  T. Usdin,et al.  Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. , 1996, The Journal of clinical investigation.

[56]  T. Moody,et al.  Differential Signaling and Immediate‐Early Gene Activation by Four Splice Variants of the Human Pituitary Adenylate CyclaseActivating Polypeptide Receptor (hPACAP‐R) , 1996, Annals of the New York Academy of Sciences.

[57]  S. Goldring,et al.  Full Activation of Chimeric Receptors by Hybrids between Parathyroid Hormone and Calcitonin , 1996, The Journal of Biological Chemistry.

[58]  Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP): Effect of a GIP-specific receptor antagonist , 1996, Regulatory Peptides.

[59]  P. Sexton,et al.  Functionally different isoforms of the human calcitonin receptor result from alternative splicing of the gene transcript. , 1995, Molecular endocrinology.

[60]  C. Nabhan,et al.  The alternatively spliced type II corticotropin-releasing factor receptor, stably expressed in LLCPK-1 cells, is not well coupled to the G protein(s). , 1995, Biochemical and biophysical research communications.

[61]  L. Miller,et al.  Critical Contributions of Amino-terminal Extracellular Domains in Agonist Binding and Activation of Secretin and Vasoactive Intestinal Polypeptide Receptors. STUDIES OF CHIMERIC RECEPTORS (*) , 1995, The Journal of Biological Chemistry.

[62]  M. Gershengorn,et al.  Alternative splicing of a 48-nucleotide exon generates two isoforms of the human calcitonin receptor. , 1995, Endocrinology.

[63]  A. Abou-Samra,et al.  Signaling properties of mouse and human corticotropin-releasing factor (CRF) receptors: decreased coupling efficiency of human type II CRF receptor. , 1995, Endocrinology.

[64]  F. Holsboer,et al.  Differential signal transduction by six splice variants of the pituitary adenylate cyclase-activating peptide (PACAP) receptor. , 1995, Biochemical Society transactions.

[65]  T. Serwold,et al.  Chimeric human calcitonin and glucagon receptors reveal two dissociable calcitonin interaction sites. , 1995, Biochemistry.

[66]  T. V. Ramabhadran,et al.  A variant of the human corticotropin-releasing factor (CRF) receptor: cloning, expression and pharmacology. , 1994, Biochemical and biophysical research communications.

[67]  P. Sexton,et al.  Isoforms of the rat calcitonin receptor: consequences for ligand binding and signal transduction. , 1994, Endocrinology.

[68]  K. Lewis,et al.  Expression cloning of a human corticotropin-releasing-factor receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[69]  Laurent Journot,et al.  Differential signal transduction by five splice variants of the PACAP receptor , 1993, Nature.

[70]  K. Beaumont,et al.  Molecular cloning of two receptors from rat brain with high affinity for salmon calcitonin , 1993, FEBS letters.

[71]  P. Sexton,et al.  Identification of brain isoforms of the rat calcitonin receptor. , 1993, Molecular endocrinology.

[72]  H. Lodish,et al.  Cloning, characterization, and expression of a human calcitonin receptor from an ovarian carcinoma cell line. , 1992, The Journal of clinical investigation.

[73]  F. Cardinaux,et al.  N-terminal truncation of salmon calcitonin leads to calcitonin antagonists. Structure activity relationship of N-terminally truncated salmon calcitonin fragments in vitro and in vivo. , 1992, Biochemical and biophysical research communications.

[74]  T. Rink,et al.  8–37h‐CGRP antagonizes actions of amylin on carbohydrate metabolism in vitro and in vivo , 1991, FEBS letters.

[75]  M. Chorev,et al.  A new highly potent parathyroid hormone antagonist: [D-Trp12,Tyr34]bPTH-(7-34)NH2. , 1988, Endocrinology.

[76]  J. T. Turner,et al.  A fragment of vasoactive intestinal peptide, VIP(10–28), is an antagonist of VIP in the colon carcinoma cell line, HT29 , 1986, Peptides.